Safety and Efficacy of CDB-2914 for Emergency Contraception

HRA Pharma1,623 enrolled

Overview

The purpose of this study is to assess the safety and efficacy of CDB-2914 for preventing pregnancy when taken 3 to 5 days after unprotected sexual intercourse.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

1,623

Conditions

Emergency Contraception

Interventions

CDB-2914DRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged 18 years or more * Menstruating women with regular menstrual cycle between 24 and 35 days and intra-individual variations less than or equal to 5 days * Request emergency contraception between 48 hours and 120 hours after unprotected intercourse as defined by lack of contraceptive use, or condom breakage (including condoms lubricated with spermicide) or other barrier contraceptive method failure * No current use of hormonal contraception and having had at least one complete menstrual cycle (2 menses) since having stopped hormonal contraception * For women with a recent history of Depo Provera use, the most recent injection must have been at least 9 months before study entry and followed by at least one complete menstrual cycle (2 menses) * Willing to not use hormonal methods of contraception until study completion * At least one complete menstrual cycle (2 menses) post delivery, miscarriage or abortion * Able to provide informed consent in English * Give voluntary, written informed consent, and agree to observe all study requirements (the subject needs to be available for follow-up over the next 6 weeks) * Willing to abstain from further acts of unprotected intercourse during participation in the study and until pregnancy status has been ascertained Exclusion Criteria: * One or more acts of one unprotected intercourse more than 120 hours before requesting emergency contraception in the current cycle * All acts of unprotected intercourse (in the current cycle) within 48 hours of presentation * Currently pregnant as confirmed by positive HSUP test performed at screening * Currently breast-feeding * Current use of hormonal contraception * Use of hormonal emergency contraception since last menstrual period * Current use of IUD * Tubal ligation * Partner with a vasectomy * Unsure about the date of the last menstrual period * Severe asthma insufficiently controlled by oral glucocorticoid * Currently enrolled in any other trial of an investigational medicine

Locations (17)

Planned Parenthood of Mar Monte

San Jose, California, United States

Planned Parenthood of the Rocky Mountains

Denver, Colorado, United States

Outcomes

Primary Outcomes

Pregnancy Rate

A high sensitivity pregnancy test was performed at inclusion (between 48h and 120h after unprotected intercourse) and then until menses occured or up to 60 days if they did not, at the following time points: * 5-7 days after expected date of menses * 1 week later * every two week after

Time frame: Up to 60 days after enrollment

Secondary Outcomes

Prevented Fraction (Number of Prevented Pregnancies Divided by the Number of Expected Pregnancies)

Number of prevented pregnancies divided by the number of expected pregnancies

Time frame: within the menstrual cycle of the unprotected Intercourse

Impact on Menstrual Bleeding Patterns

Menstrual cycle length post treatment

Time frame: within the menstrual cycle of the unprotected Intercourse

Frequencies of Subjects With Treatment Emergent Adverse Events

Most common related adverse events in ITT population.

Time frame: 12-14 days after expected menses

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.